"Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer"

NCT06829355 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

MCRC

Interventions

DRUG: Thymalfasin (Thymosin alpha 1, Ta1)
DRUG: Regorafenib (BAY 73-4506)
DRUG: Tislelizumab (BGB-A317)

Sponsor

Beijing Friendship Hospital

Collaborators

[object Object]
[object Object]